Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04493827

Enrollment

114

Registered

2020-07-30

Start date

2011-01-31

Completion date

2019-12-31

Last updated

2020-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic, Adenocarcinoma of Lung Stage IV

Brief summary

The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Lung adenocarcinoma * Patients diagnosed at a metastatic stage * Patient who benefited an oncogenic driver research on their histologic samples * Medical follow-up entirely done in Nancy Central Hospital

Exclusion criteria

* Patients with double histology * Synchronous cancer * Patients with surgical care

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	over a period of 5 years (Day 0 = anatomopathological diagnosis)	Time (in months) from anatomopathological diagnosis to death
Progression Free survival	over a period of 5 years (Day 0 = anatomopathological diagnosis)	Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria
Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma	At base line (Day 0 = anatomopathological diagnosis)	Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas

Secondary

Measure	Time frame	Description
Distribution in percentage of metastasis sites according oncogenic drivers	At baseline (Day 0 = anatomopathological diagnosis)	Distribution in percentage of metastatic sites assessed by CT-scan for metastatic lung adenocarcinomas according oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2)

Countries

France

Outcome results